Progyny

PGNY

Market cap $2.07B

CEO Anevski now owns $17 million worth of Progyny. Progyny's stock popped roughly 8% the day of the announcement.

Progyny (PGNY) possesses solid growth attributes, which could help it handily outperform the market.

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in family building solutions, today announced new men's health research exploring experiences and views on fertility. The findings shed light on how men in the U.S. view their role in the fertility journey and the barriers that prevent many from getting the care they need for successful conception.

Progyny (PGNY) surges after strong Q3 earnings, robust client growth, and a $200M share buyback, signaling renewed momentum and market confidence. PGNY overcame Amazon's departure by adding new clients, achieving near 100% renewal rates, and accelerating revenue growth across both business segments. Analyst upgrades, insider buying, and secular tailwinds—like rising infertility and delayed childbirth—support a bullish outlook and reinforce the company's competitive moat.

Progyny is a leader in fertility benefits, offering employers comprehensive, outcomes-based solutions that improve treatment success and manage costs. Its focused model has driven strong demand and set it apart in a niche that's expanding quickly within the healthcare sector.

Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Investors interested in stocks from the Medical Services sector have probably already heard of Progyny (PGNY) and HealthEquity (HQY). But which of these two stocks is more attractive to value investors?

NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that Mark Livingston, Progyny's Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 3:00 p.m. GMT / 10:00 a.m. ET.

Progyny's third-quarter results were exceptional. Sales grew by 9% and were up by 23% on an adjusted basis, accounting for the loss of a major customer last year.

Progyny, Inc. ( PGNY ) Q3 2025 Earnings Call November 6, 2025 4:45 PM EST Company Participants James Hart - Vice President of Investor Relations Peter Anevski - CEO & Director Mark Livingston - Chief Financial Officer Michael Sturmer - President Conference Call Participants Jailendra Singh - Truist Securities, Inc., Research Division Brian Tanquilut - Jefferies LLC, Research Division Michael Cherny - Leerink Partners LLC, Research Division Scott Schoenhaus - KeyBanc Capital Markets Inc., Research Division Nisala Devanath Weerasuriya - BofA Securities, Research Division David Larsen - BTIG, LLC, Research Division Presentation Operator Good afternoon, and welcome to the Progyny, Inc. Earnings Conference Call. [Operator Instructions] I'd now like to turn the call over to your host, James Hart.